RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC15H19N3O2

InChIKeyRLCLASQCAPXVLM-NSHDSACASA-N

CAS Registry1642288-47-8

Clinical Trials associated with Mavacamten

NCT07103655

/ Not yet recruitingPhase 4IIT

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.

This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.

Start Date01 Jan 2026

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT07004972

/ RecruitingPhase 4

A Phase 4, Single-Arm, Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy in India

The purpose of this study is to evaluate the safety, tolerability and effectiveness of mavacamten in adults with obstructive hypertrophic cardiomyopathy in India.

Start Date04 Sep 2025

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT07120776

/ Not yet recruitingNot ApplicableIIT

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in Hypertrophic Obstructive Cardiomyopathy: The PEACH Trial

Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction). Often individuals with HOCM suffer from chest pain and shortness of breath due to lack of oxygen supply (ischaemia) to the heart muscle in the absence of blockages in the coronary arteries.
Despite proven advances in treatment of LVOT obstruction with the novel medication Camzyos (Mavacamten), there is a limited understanding of its effect on myocardial ischaemia.
This study, called the PEACH Trial, is designed to assess whether Camzyos also improves blood supply (perfusion) to the heart muscle in patients with HOCM. A specialised imaging technique called Positron Emission Tomography/Computed Tomography (PET-CT), using Rubidium-82 will be used to evaluate blood flow to the heart muscle before and after treatment. Camzyos is part of participants' regular clinical treatment and is not being supplied, administered, or influenced by the study in any way.
Participants with HOCM who are starting treatment with Camzyos as part of their clinical care will undergo a baseline PET-CT scan (if not already done), and a second scan after 12 months. The follow-up scan is done solely for research purposes. The scans will allow researchers to evaluate whether the medication improves myocardial perfusion in addition to relieving outflow obstruction.
The study is sponsored by the University of Manchester and funded by Bristol Myers Squibb. It will involve up to 75 participants recruited at Manchester University NHS Foundation Trust. The findings could help improve understanding of how Camzyos works and support personalised treatment approaches in HOCM.

Start Date01 Sep 2025

Sponsor / Collaborator

The University of Manchester

100 Clinical Results associated with Mavacamten

100 Translational Medicine associated with Mavacamten

100 Patents (Medical) associated with Mavacamten

408

Literatures (Medical) associated with Mavacamten

01 Feb 2026·AMERICAN HEART JOURNAL

Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial

Article

Author: Mital, Seema ; Crevar, Christina ; Dyme, Joshua ; Rossano, Joseph ; Favatella, Nicholas ; Puli, Shilpa ; Wolf, Cordula ; Canter, Charles ; Lockman, Jeffrey ; Javidialsaadi, Atefeh

BACKGROUND:

Mavacamten, a first-in-class cardiac myosin inhibitor, is approved internationally for the treatment of symptomatic adult patients with obstructive hypertrophic cardiomyopathy (HCM) and has been shown to improve cardiac function and symptoms in adult patients across multiple phase 3 trials. The efficacy and safety of mavacamten in pediatric patients with obstructive HCM has not been evaluated.

METHODS:

SCOUT-HCM is a phase 3, randomized, placebo-controlled, double-blind, parallel-group, multicenter, international study in symptomatic adolescent patients (12 years to <18 years old) with obstructive HCM. The aim of the study is to assess the efficacy, safety, and pharmacokinetics of mavacamten in this population. Participants will be randomized 1:1 to mavacamten or placebo for 28 weeks, followed by a 28-week active-treatment period (when patients randomized to placebo will cross over to mavacamten) and an open-label long-term extension period for ≤144 weeks. Participants will initiate mavacamten at a dosage of 2.5 mg/day or 5 mg/day; dose titration will be based on echocardiographic assessment of Valsalva left ventricular (LV) outflow tract (LVOT) gradient and LV ejection fraction. The primary endpoint is change from baseline to week 28 in Valsalva LVOT gradient. Secondary endpoints include efficacy parameters of resting and post-exercise LVOT gradients, peak oxygen consumption, symptoms, and health status, plus safety and pharmacokinetic parameters.

CONCLUSIONS:

SCOUT-HCM is the first clinical trial to evaluate a cardiac myosin inhibitor in adolescent patients with obstructive HCM. SCOUT-HCM will assess the utility of mavacamten in this patient population with an unmet clinical need.

TRIAL REGISTRATION:

ClinicalTrials.gov: NCT06253221.

01 Jan 2026·INTERNATIONAL JOURNAL OF CARDIOLOGY

Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients as early as one week of treatment in obstructive hypertrophic cardiomyopathy

Article

Author: Polestyuk, Bianka ; Borbás, János ; Takács, Hedvig ; Kormányos, Árpád ; Pálinkás, Attila ; Nagy, Viktória ; Boda, Krisztina ; Rácz, Gergely ; Sepp, Róbert ; Schvartz, Noémi ; Pintér, Jenő Antal ; Szili-Török, Tamás ; Szűcsborus, Tamás ; Vidács, László Dániel

BACKGROUND:

Real-world data on the efficacy of mavacamten, indicated for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), are relatively scarce, particularly in patients with extreme left ventricular outflow tract (LVOT) gradients and concerning its short-term effects.

PATIENTS/METHODS:

We investigated a cohort of twenty-five oHCM patients [15 men (60 %), mean age: 55 ± 11 years], with a resting or provoked LVOT gradient of >100 mmHg, receiving mavacamten treatment. Patients underwent a complete standard and 2D-speckle tracking echocardiographic examination after one week (W1) of treatment initiation and at subsequent four-week intervals.

RESULTS:

After only one week of mavacamten therapy, both the resting peak LVOT gradient (from 121 to 87 mmHg) and the Valsalva gradient (from 167 to 129 mmHg) significantly decreased (all p < 0.001), showing further decrease (resting gradient: to 67 mmHg at W4, and to 56 mmHg at W8; Valsalva gradient to 102 mmHg at W4, and to 80 mmHg at W8, all p < 0.001). NTproBNP levels also significantly decreased already at W1 (-1467 pg/ml), showing further decrease during treatment (-1735 pg/ml at W4, and - 2048 pg/ml at W8; all p < 0.001). NYHA functional class, 6-min walk distance, parameters of myocardial work and many of the assessed diastolic parameters showed significant improvements and no change in LV ejection fraction or global longitudinal strain was observed.

CONCLUSIONS:

Mavacamten effectively reduced even >100 mmHg LVOT gradients and led to significant gradient reduction already in one week. Besides favourable changes in LVOT obstruction, structural and functional echocardiographic parameters, functional capacity, and cardiac biomarkers, it also led to significant improvement in myocardial work parameters.

01 Dec 2025·Journal of cardiovascular imaging

Cardiac myosin inhibitors in hypertrophic cardiomyopathy

Review

Author: Lim, Jaehyun ; Kim, Hyung-Kwan

Abstract:

Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular outflow tract (LVOT) obstruction in obstructive HCM. In the EXPLORER-HCM trial, mavacamten significantly improved exercise capacity, symptoms, and LVOT pressure gradients, while the VALOR-HCM trial proved it can obviate the need for septal reduction therapy in patients who were deemed to be candidates for septal reduction therapy. Notably, long-term data (MAVA-LTE study) has demonstrated sustained benefits up to 180 weeks, with < 10% experiencing transient reductions in left ventricular ejection fraction < 50% and only 1.3% of permanent discontinuation rate. Aficamten, a next-generation CMI with a shorter half-life, has also demonstrated comparable efficacy. Reverse remodeling following treatment was noted in both agents. In nonobstructive HCM, preliminary studies (MAVERICK-HCM trial and cohort 4 of REDWOOD-HCM trial) have reported improvements in cardiac serum biomarkers and symptoms. However, the preliminary results from phase 3 trials (ODYSSEY-HCM trial) revealed that primary endpoints were not met in nonobstructive HCM. Regarding safety, both were generally well tolerated. Although an LVEF reduction occurred in some patients, it was reversible with a dose reduction or a short-term drug cessation. These results emphasize careful dosing strategy with regular echocardiographic monitoring. Real-world data have also demonstrated consistent efficacy and safety across varying ethnic groups without new safety signals. CMI is a major advance in HCM management. However, future studies must provide data on hard clinical outcomes, such as heart failure hospitalization or death. Ongoing trials comparing CMI to traditional first-line therapies, such as β-blockers, will clarify their potential role as an initial therapeutic option.

225

News (Medical) associated with Mavacamten

05 Nov 2025

·www.fiercebiotech.com

Braveheart Bio launches with mission to conquer heart disease market, capturing $185M series A

Braveheart Bio is armed with investor backing from Forbion and OrbiMed, among others. \n With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena.Backed by investors including Forbion, OrbiMed, Enavate Sciences, Fraizer Life Sciences and Andreessen Horowitz, the biotech recently catapulted itself into the increasingly heated hypertrophic cardiomyopathy (HCM) landscape with a $65 million deal for a selective myosin inhibitor from China\'s Jiangsu Hengrui Pharmaceuticals.Now referred to as BHB-1893, the drug candidate is a potential rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten. While Camzyos currently has a choke hold on the commercial market for HCM, Braveheart’s CEO Travis Murdoch, M.D., says the available treatments for the heart disease “leave room for improvement.”“We see potential for our investigational cardiac myosin inhibitor to a best-in-class molecule that enhances the efficacy, safety and convenience of care for patients and prescribers,” Murdoch said in a Nov. 5 press release, adding that he is “delighted” to lead Braveheart’s “highly talented and expanding team.”The company’s leadership line-up offers a “rare combination of cardiovascular drug development expertise and a demonstrated track record of building late-stage companies,” as its board director Jasper Bos, Ph.D., put it in the release. At the helm of the board is Chairman Chris Viehbacher, a well-known biopharma veteran who currently leads Biogen as CEO. In a statement, Viehbacher called Braveheart an “exciting company with an excellent team” that is “positioned well to advance BHB-1893 with rigor and drive.\"Murdoch and Viehbacher previously shook hands on Biogen’s $1.15 billion buyout of HI-Bio, an immunology-focused biotech Murdoch founded in 2021. Murdoch then worked under Viehbacher for a year as the head of Biogen’s West Coat hub before pivoting to Braveheart and rounding up a slew of experienced executives, including HI-Bio\'s former head of regulatory affairs, Michele Anderson, as chief development officer. For more than a year, the team searched across the globe for “novel, potentially transformative treatments” before landing on BHB-1893, board director Erez Chimovits explained in the release.Braveheart plans to initiate late-stage clinical development of the drug next year with the goal of establishing a new standard of care, it said. Early data presented at the European Society of Cardiology Congress 2025 suggested that BHB-1893 can achieve rapid and clinically meaningful reduction in left ventricular outflow tract gradients, a blood pressure measure that can speak to the severity of an HCM obstruction, within days of treatment initiation for patients with obstructive HCM, according to Braveheart. HCM is a genetic heart condition that impacts about one in every 500 people in the U.S., causing risks of heart failure, stroke or sudden cardiac death. The disease is marked by an abnormally thick heart muscle, particularly in the left ventricle, which can be linked to overactive myosin protein.In about two-thirds of patients, the thickened muscle creates a blockage in the heart’s main pumping chamber, a condition referred to as obstructive HCM.BMS’ 2022 approval for Camzyos made it the first marketed cardiac myosin inhibitor meant to target the source of obstructive HCM. Rival Cytokinetics, meanwhile, is expecting an FDA decision this year for its aficamten, which is expected to put pressure on Camzyos.

Drug ApprovalExecutive ChangeAcquisition

05 Nov 2025

·firstwordpharma.com

Heart disease startup Braveheart Bio makes debut, backed by $185M

Braveheart Bio is stepping into an increasingly competitive hypertrophic cardiomyopathy (HCM) space with $185 million in series A funding and a leadership team seasoned in cardiovascular drug development. Its backers include Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences and Frazier Life Sciences, with Biogen CEO Chris Viehbacher taking the chair of Braveheart's board."Braveheart is an exciting company with an excellent team and real potential to make an impact for patients," Viehbacher said.The San Francisco-based startup, which launched Wednesday, is working on an experimental cardiac myosin inhibitor, BHB-1893, that it hopes will combine efficacy with a safety profile that could support simpler dosing. The drug, also known as HRS-1893, was originally discovered by Jiangsu Hengrui Pharmaceuticals, which recently out-licensed ex-China rights to Braveheart in a deal worth up to $1.1 billion."We see potential for our investigational cardiac myosin inhibitor to be a best-in-class molecule that enhances the efficacy, safety and convenience of care for patients and prescribers," said Braveheart CEO Travis Murdoch.Treatment options for HCM have historically centred on beta blockers and invasive surgery, until the arrival of Bristol Myers Squibb's cardiac myosin inhibitor Camzyos (mavacamten) in 2022. Marc Evanchik, Braveheart's SVP of pharmacology and translational medicine, headed pharmacology for over four years at MyoKardia, which originally developed Camzyos before being bought by BMS in 2020 for $13.1 billion.Camzyos received updated labelling earlier this year that reduced some of its monitoring requirements and eased certain restrictions. Cytokinetics, meanwhile, is developing aficamten, a similar drug currently under review for obstructive HCM at the FDA, where a decision is expected by Dec. 26 (see – Spotlight On: Key PDUFA dates to watch in 4Q25).BHB-1893 is a small-molecule inhibitor designed to dial down cardiac over-contraction more precisely. Early data presented at the recent European Society of Cardiology (ESC) showed "rapid and clinically meaningful reduction in left ventricular outflow tract gradients within days of treatment initiation, [and] a shallow ejection fraction exposure response curve," according to Braveheart.The candidate has advanced through Phase II trials in both symptomatic obstructive HCM and non-obstructive HCM, as well as an ongoing Phase III trial in China. Braveheart plans to initiate global late-stage development for BHB-1893 in 2026.

AcquisitionPhase 2

05 Nov 2025

·www.biopharmadive.com

Braveheart secures $185M to advance challenger to Bristol Myers heart drug

Dive Brief:Braveheart Bio formally debuted on Wednesday with $185 million in Series A funding thatll support development of a drug it envisions as a best-in-class treatment for a heart condition known as hypertrophic cardiomyopathy. That drug, BHB-1893, was licensed from China-based Hengrui Pharma in a deal announced in September. Before assigning most commercial rights to Braveheart, Hengrui previously brought the drug into mid-stage testing in the non-obstructive form of the disease and a Phase 3 study, in China, in the obstructive type. Braveheart will begin global late-stage testing in 2026. Braveheart is led by Travis Murdoch, the former CEO of an immunology startup, HI-Bio, that Biogen acquired last year. Its chaired by Biogen CEO Chris Viehbacher and backed by about half a dozen prominent investment firms, among them Andreessen Horowitz, Forbion and OrbiMed. Dive Insight:Braveheart is one of many startups to recently turn to China-originated companies to build a pipeline. Its licensing deal with Hengrui, worth potentially more than $1 billion, was one of at least 20 between Chinese biotechs and privately held U.S. or European companies this year, according to BioPharma Dive data.These deals are enabling new companies to start up with drugs that, in many instances, are already in clinical testing and seen as potentially better versions of other therapies either in testing or on the market. Theyve become so prominent theyve caught the attention of lawmakers in Washington D.C., which just last week held a hearing discussing reforms that might help U.S. research labs and the companies built around their work better compete.Murdoch noted how he pursued an in-licensing strategy in forming HI-Bio, which was built around a drug acquired from Germany. With Braveheart, the executive team and the funds supporting it looked around the world, not just China, for promising drugs, he said.This particular molecule stood out in that search for its potential, he said,so this is really a story about finding the most compelling molecule.That molecule is a possible threat to Camzyos, a Bristol Myers Squibb medicine that in 2022 became the first approved treatment for the obstructive and more common form of the progressive heart condition hypertrophic cardiomyopathy. Camzyos is currently still the only drug available for the disease and generated $843 million in sales over the first nine months of the year. But it may soon face competition. A drug from Cytokinetics could be approved later this year and others, including Bravehearts, are advancing through testing.All of these medicines are so-called cardiac myosin inhibitors. Theyre designed to make the hearts contractions less forceful, which, in turn, is meant to help alleviate symptoms associated with the condition. But while these drugs have helped improve heart function and how patients feel, theres still a significant unmet need, Murdoch told BioPharma Dive.Many patients still have evidence of a blockage, or that their hearts have a reduced ability to pump out blood, he said. The complex dosing schedule and risk mitigation protocol associated with Camzyos has also limited uptake. Additionally, none of the experimental medicines have yet succeeded in a Phase 3 study in the non-obstructive type of HCM, which is estimated to account for about a third of the people with the condition.Braveheart, for its part, claimed in a statement that BHB-1893 has the potential to be a best-in-class molecule that enhances the safety, efficacy, and convenience of care for patients and doctors. Phase 1 data were presented at a medical meeting in August and demonstrated rapid and clinically meaningful impact on blood flow out of the heart as well as a safety profile supporting a simple dosing regime, the company said.In a field where drugs have had to be titrated and closely monitored, we think there is an emerging profile for a drug that could address the underlying mechanism of disease, have an impact quickly, and act in a way that allows for more ease of prescribing, Murdoch added. We think that would be a differentiated profile, should it bear out through our late-stage program. '

Phase 3Phase 1Drug ApprovalLicense out/in

100 Deals associated with Mavacamten

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14921

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertrophic obstructive cardiomyopathy	United States	Bristol Myers Squibb Co.	28 Apr 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	United States	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	China	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Japan	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Australia	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Austria	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Belgium	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Brazil	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Canada	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Czechia	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Denmark	Bristol Myers Squibb Co.	14 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05174416 (EXPLORER-CN, Pubmed \| JACC Asia)	Phase 3	Hypertrophic obstructive cardiomyopathy	81	Mavacamten	jthaoquwje(wuswnmduct) = qaoeloszai itcdejniry (ulreekqjdv, -41.5 to -20.1) View more	Positive	01 Aug 2025
NCT03470545 (EXPLORER-HCM, Pubmed \| J Card Fail)	Phase 3	Hypertrophic obstructive cardiomyopathy	-	mavacamten (Age ≤60 years)	fwedskpqkt(hxuwzowcul) = dkqqhzhiua qjctpzemtv (zaufjqyato ) View more	Positive	01 Jun 2025
				mavacamten (Age >60 years)	fwedskpqkt(hxuwzowcul) = swibbmoghj qjctpzemtv (zaufjqyato ) View more
NCT05174416 (EXPLORER-CN, Pubmed \| Cardiol Ther)	Phase 3	Hypertrophic obstructive cardiomyopathy	81	Mavacamten	ldjckjhksz(iwrnwbxbec): P-Value = < 0.001 View more	Positive	29 Apr 2025
				Placebo
NCT05582395 (ODYSSEY-HCM, Company_Website) Manual	Phase 3	Hypertrophic Cardiomyopathy without Obstruction	580	Camzyos	snmmhgrrfs(mqleyctffw) = did not meet puephcuyoq (elbpighvjl ) Not Met View more	Negative	14 Apr 2025
				Placebo
NCT04766892 (EMBARK-HFpEF, CTgov)	Phase 2	Heart failure with normal ejection fraction	30	Mavacamten	vyczhlngec = kfruzvlauw ktcunpknmx (gpbuoqfkud, goyurmjuql - orudnhqzik) View more	-	20 Mar 2025
NCT03496168 (PIONEER-OLE, CTgov)	Phase 2	Hypertrophic obstructive cardiomyopathy	13	Mavacamtem (Mavacamtem)	etaittntiz = hkvodcdnci gpqvwjmpch (vforgzdjps, bgzvupvqek - pypdmrqcxi) View more	-	09 Jan 2025
				Mavacamten (Mavacamten)	uaqnumivjp(dsoirgctbe) = zqtnofcved ouxeunzayf (rltgsptcps, dzyqrrntps - wnlzosnsfs) View more
NCT05414175 (HORIZON-HCM, CTgov)	Phase 3	Hypertrophic obstructive cardiomyopathy	38	Mavacamten	bwuvlfqipz(duknpynueu) = acvvbkqvxl xcuxsnyzqm (fysypqdsak, 31.55674) View more	-	04 Dec 2024
NCT04766892 (EMBARK-HFpEF, Pubmed \| JAMA Cardiol)	Phase 2	Heart failure with normal ejection fraction N-terminal pro-B-type natriuretic peptide (NTproBNP) \| high-sensitivity troponin T (hsTnT) \| high-sensitivity troponin I (hsTnI)	30	Mavacamten 2.5 mg	wjhymmdddh(yefmhgfmed) = qltqzsfxkz ipanmniigv (zwlyzfrbro, -44% - -4%)	Positive	30 Sep 2024
NCT05174416 (EXPLORER-CN, CTgov)	Phase 3	Hypertrophic obstructive cardiomyopathy	81	Mavacamten (Mavacamten)	zvktlecjfl(ivinxngwnz) = wqbyiqtizh gifmofhugp (irvijfeshi, 6.150) View more	-	19 Sep 2024
				Placebo (Placebo)	zvktlecjfl(ivinxngwnz) = avyhcgxjwr gifmofhugp (irvijfeshi, 8.535) View more
NCT03723655 (EXPLORER-LTE, BusinessWire) Manual	Phase 3	Hypertrophic obstructive cardiomyopathy	251	CAMZYOS® (mavacamten)	ieutjufbch(igtetiraoj) = eeovjqsbnu pqxyxqdque (vpoviudcon ) View more	Positive	01 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis